Viridian Therapeutics, Inc.\DE

VRDN

Viridian Therapeutics, Inc.\DE

VRDN

Insider Sentiment (TTM):

Last Purchase:2026-05-11Last Sale:2025-12-31Shares Purchased (TTM):1,631,015Shares Sold (TTM):2,272

Institutional Sentiment:

As of:2025-09-30Institutional Shares Owned:4,180Shares Outstanding:81,784,499Institutional Ownership Pct.:0.01%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	165	176	212	170	117	116	100	200	108	92	103	112
Available For Sale Securities Debt Securities Curr…	817	586	662	321	446	520	618	553	464	522	375	201
Contract With Customer Asset Net Current	-	-	-	70	-	-	-	-	-	-	-	-
Prepaid Expense And Other Assets Current	25	23	20	11	15	21	21	14	10	14	9	11
Contract With Customer Asset Net	-	-	-	-	-	-	0	0	0	0	0	0
Assets Current	1,081	785	894	572	579	657	738	767	582	627	486	324
Property Plant And Equipment Net	3	1	1	1	1	1	1	1	2	2	2	2
Operating Lease Right Of Use Asset	2	2	2	3	2	2	2	2	2	1	2	2
Other Assets Noncurrent	1	1	2	2	1	0	1	1	1	1	1	1
Assets	1,097	789	899	577	582	661	742	772	586	630	490	329
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	9	13	9	10	9	4	2	6	3	3	2	4
Accrued Liabilities Current	55	38	62	41	35	30	46	35	30	23	24	19
Long Term Debt Current	-	-	-	-	8	-	-	-	3	-	-	-
Liabilities Current	64	52	71	51	53	34	48	41	37	26	27	23
Long Term Debt	-	-	-	-	-	-	-	-	-	20	20	20
Long Term Debt Noncurrent	-	-	-	21	12	21	21	21	17	-	20	-
Contract With Customer Liability Noncurrent	-	-	-	-	0	0	0	0	0	1	1	1
Secured Long Term Debt	0	50	50	-	-	-	21	-	-	-	-	-
Contract With Customer Liability Current	-	-	0	-	0	0	0	0	0	0	0	0
Derivative Liabilities Noncurrent	14	13	20	-	-	-	0	-	-	-	-	-
Other Long Term Debt Noncurrent	114	36	34	-	-	-	0	-	-	-	-	-
Other Liabilities Noncurrent	2	2	2	3	2	2	2	2	2	1	1	1
Liabilities	435	153	177	74	67	57	71	64	56	48	48	45
Stockholders Equity
Common Stock Value	1	1	1	1	1	1	1	1	1	1	1	0
Additional Paid In Capital	2,135	1,947	1,927	1,531	1,509	1,497	1,478	1,433	1,169	1,157	961	807
Accumulated Other Comprehensive Income Loss Net Of…	-1	-1	0	0	0	0	-0	1	-1	-0	0	-0
Retained Earnings Accumulated Deficit	-1,570	-1,443	-1,338	-1,218	-1,184	-1,083	-996	-916	-839	-774	-726	-659
Stockholders Equity	662	636	722	503	515	604	672	707	529	583	442	284
Liabilities And Stockholders Equity	1,097	789	899	577	582	661	742	772	586	630	490	329
Related Party	-	-	-	-	0	0	1	3	-1	1	0	-1
Series A Preferred Stock	-	0	0	0	-0	0	0	-0	0	0	0	0
Series B Preferred Stock	-	0	0	0	-0	0	0	0	0	0	0	0
Preferred Stock Par Or Stated Value Per Share	-	-	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Preferred Stock Shares Authorized	-	-	5	5	5	5	5	5	5	5	5	5
Common Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	113	102	102	82	82	82	81	79	64	64	54	44
Shares Outstanding	113	102	102	82	82	82	81	79	64	64	54	44

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-6.03%	-4.53%	2.77%	-	-	-	-	-	-	-	-	-
2025	15.71%	19.12%	43.64%	6.86%	17.38%	28.84%	30.88%	30.55%	34.85%	-8.51%	-49.81%	-42.96%
2024	-19.80%	-12.68%	11.81%	-2.91%	54.30%	52.45%	-12.08%	-9.99%	-13.60%	0.21%	-6.32%	-5.83%
2023	-	-	-	1.92%	-18.19%	-33.97%	29.66%	51.68%	34.74%	-8.16%	-25.55%	-31.41%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	16.95	15.15	12.65	11.28	11.01	19.49	15.43	18.55	15.82	23.99	18.26	13.93
Quick Ratio	16.56	14.71	12.37	11.06	10.71	18.88	14.99	18.21	15.54	23.47	17.93	13.47
Working Capital	1.02B	732.94M	823.54M	521.22M	526.17M	623.51M	690.59M	725.99M	544.90M	600.69M	459.84M	300.59M
Leverage & Debt
Debt to Equity	0.66	0.24	0.25	0.15	0.13	0.09	0.11	0.09	0.11	0.08	0.11	0.16
Interest Coverage TTM	-25.89	-49.07	-73.44	-155.65	-178.90	-156.02	-136.11	-107.66	-92.88	-104.84	-137.76	-211.14
Debt Ratio	0.40	0.19	0.20	0.13	0.12	0.09	0.10	0.08	0.10	0.08	0.10	0.14
Efficiency & Turnover
Asset Turnover TTM	0.08	0.10	0.09	0.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-	-3.53	-4.04	-3.69	-4.22	-3.79	-3.98	-3.87	-3.57	-3.57	-5.31	-4.96
Free Cash Flow Per Share TTM	-2.96	-2.97	-3.27	-3.99	-3.79	-3.45	-3.43	-2.97	-2.64	-2.75	-4.14	-4.15
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-569.68%	-543.86%	-512.91%	-463.51%	-121,830.82%	-111,590.73%	-99,018.21%	-93,722.52%	-87,078.47%	-82,595.14%	-81,035.03%	-66,869.74%
Net Profit Margin TTM	-544.06%	-508.46%	-483.57%	-426.58%	-112,806.89%	-102,092.38%	-89,387.09%	-85,127.15%	-79,185.76%	-75,737.85%	-75,711.46%	-62,437.75%
Growth Metrics
Net Revenue Growth (1Y)	23,220.33%	23,382.78%	23,359.93%	23,340.07%	5.90%	4.86%	-3.82%	-12.97%	-80.41%	-82.59%	-82.28%	-81.55%
Net Income Growth (1Y)	12.47%	16.95%	26.91%	17.46%	50.87%	41.35%	13.55%	18.66%	15.24%	26.57%	83.05%	91.67%
EPS Growth (1Y)	-18.96%	-6.92%	1.60%	-4.61%	18.07%	6.17%	-25.14%	-22.01%	-21.94%	-12.49%	31.24%	48.15%
Valuation Metrics
P/E TTM	-5.38	-5.54	-7.70	-5.84	-3.32	-3.56	-4.82	-5.88	-3.64	-4.90	-4.10	-3.09
P/B TTM	3.14	3.14	3.65	3.51	2.21	1.81	1.94	2.14	1.57	1.84	2.21	2.36
P/S TTM	29.25	28.19	37.25	24.93	3,739.92	3,630.86	4,309.18	5,003.50	2,884.54	3,714.74	3,104.38	1,929.86
Market Cap	2.08B	2.00B	2.64B	1.76B	1.14B	1.10B	1.30B	1.51B	830.75M	1.07B	974.77M	669.66M
Enterprise Value	1.92B	1.87B	2.48B	1.62B	1.04B	1.00B	1.22B	1.33B	743.53M	998.53M	892.15M	578.06M
Calculated Values
Free Cash Flow TTM	-335.04M	-303.82M	-276.89M	-326.34M	-309.60M	-280.35M	-232.83M	-197.43M	-168.82M	-168.20M	-185.07M	-181.29M
Net Debt	-164.99M	-125.91M	-162.44M	-148.76M	-96.54M	-95.53M	-79.01M	-179.79M	-87.22M	-71.31M	-82.62M	-91.60M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-11Purchase

Owner: Fairmount, Healthcare Fun…

Title: -

Shares: 1,176,470

Price/Share: $17.00

Value: $19,999,990.00

Shares Owned: 5,090,928

Relationship: Director,TenPercentOwner

Ownership: Indirect

2025-12-31Sale

Owner: Tousignant, Jennifer

Title: Chief Legal Officer

Shares: 2,272

Price/Share: $31.16

Value: $70,795.52

Shares Owned: -

Relationship: Officer

Ownership: Direct

2025-10-23Purchase

Owner: Fairmount, Healthcare Fun…

Title: -

Shares: 454,545

Price/Share: $22.00

Value: $9,999,990.00

Shares Owned: 3,914,458

Relationship: Director,TenPercentOwner

Ownership: Indirect

2024-09-27Purchase

Owner: Mahoney, Stephen F.

Title: President and CEO

Shares: 21,400

Price/Share: $23.33

Value: $499,262.00

Shares Owned: 21,400

Relationship: Director,Officer

Ownership: Direct

2024-09-27Purchase

Owner: Beetham, Thomas W.

Title: Chief Operating Officer

Shares: 5,000

Price/Share: $23.41

Value: $117,050.00

Shares Owned: 6,000

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-11	Fairmount, Healthcare Fun…	Director,TenPercentOwner	-	Indirect	Purchase	1,176,470	17.00	$19,999,990.00	5,090,928	4
2025-12-31	Tousignant, Jennifer	Officer	Chief Legal Officer	Direct	Sale	2,272	31.16	$70,795.52	0	4
2025-10-23	Fairmount, Healthcare Fun…	Director,TenPercentOwner	-	Indirect	Purchase	454,545	22.00	$9,999,990.00	3,914,458	4
2024-09-27	Mahoney, Stephen F.	Director,Officer	President and CEO	Direct	Purchase	21,400	23.33	$499,262.00	21,400	4
2024-09-27	Beetham, Thomas W.	Officer	Chief Operating Officer	Direct	Purchase	5,000	23.41	$117,050.00	6,000	4
2024-09-13	Fairmount, Healthcare Fun…	Director,TenPercentOwner	-	Indirect	Purchase	1,600,000	18.75	$30,000,000.00	3,445,813	4
2024-01-22	Fairmount, Healthcare Fun…	Director,Other	-	Indirect	Purchase	476,190	21.00	$9,999,990.00	1,839,954	4
2023-06-16	Meisner, Lara	Officer	Chief Legal Officer	Direct	Sale	27	28.35	$765.45	29,971	4
2023-06-06	Meisner, Lara	Officer	Chief Legal Officer	Direct	Sale	5,126	25.02	$128,252.52	29,971	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2025-09-30

0.01%

Inst. Shares: 4,180

Shares Outstanding: 81,784,499

2025-06-30

0.01%

Inst. Shares: 7,180

Shares Outstanding: 81,593,463

2025-03-31

0.01%

Inst. Shares: 7,180

Shares Outstanding: 81,344,134

2024-12-31

0.01%

Inst. Shares: 7,500

Shares Outstanding: 67,885,831

2024-09-30

0.01%

Inst. Shares: 7,000

Shares Outstanding: 66,420,063

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2025-09-30	4,180	81,784,499	0.01%
2025-06-30	7,180	81,593,463	0.01%
2025-03-31	7,180	81,344,134	0.01%
2024-12-31	7,500	67,885,831	0.01%
2024-09-30	7,000	66,420,063	0.01%
2024-06-30	7,500	63,854,514	0.01%
2024-03-31	7,700	61,099,038	0.01%
2023-09-30	500	43,654,577	0.00%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Viridian Therapeutics, Inc.\DE (VRDN) — SEC Financial Statements & Analysis

Viridian Therapeutics, Inc.\DE (VRDN) is a pharmaceutical preparations company, incorporated in DE. Viridian Therapeutics, Inc.\DE trades on Nasdaq as: VRDN. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Viridian Therapeutics, Inc.\DE reported a 23220.33% year-over-year revenue growth, a Debt-to-Equity ratio of 0.66x, a Price-to-Sales (P/S) ratio of 29.25x (TTM), a Price-to-Book (P/B) ratio of 3.14x (TTM), at a market cap of $2.08B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 23220.33%
Debt To Equity: 0.66x
P/S TTM: 29.25x
P/B TTM: 3.14x
Market Cap: $2.08B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Viridian Therapeutics, Inc.\DE in?

Viridian Therapeutics, Inc.\DE (VRDN) operates in the Pharmaceutical Preparations industry.

What is VRDN's market cap?

Viridian Therapeutics, Inc.\DE (VRDN) has a market capitalization of $2.08B as of 2026-06-30.

What exchange does VRDN trade on?

Viridian Therapeutics, Inc.\DE (VRDN) trades on the Nasdaq.

Where is Viridian Therapeutics, Inc.\DE incorporated?

Viridian Therapeutics, Inc.\DE is incorporated in DE.